Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: hypromellose; stearic acid; indigo carmine aluminium lake; purified talc; calcium silicate; citric acid monohydrate; amaranth aluminium lake; macrogol 6000; povidone; hyprolose; titanium dioxide; diethyl phthalate; polyvinyl acetate phthalate; magnesium stearate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: purified talc; amaranth aluminium lake; titanium dioxide; stearic acid; magnesium stearate; macrogol 6000; indigo carmine aluminium lake; polyvinyl acetate phthalate; calcium silicate; diethyl phthalate; povidone; hypromellose; citric acid monohydrate; hyprolose - epilepsy: primary generaliszed epilepsies (petit mal absences, various forms of myoclonic epilepsies and tonic-clonic grand mal seizures). partial (focal) epilepsies either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: purified talc; magnesium stearate; titanium dioxide; stearic acid; indigo carmine aluminium lake; calcium silicate; polyvinyl acetate phthalate; hypromellose; citric acid monohydrate; diethyl phthalate; hyprolose; amaranth aluminium lake; povidone; macrogol 6000 - epilepsy: primary generalised epilepsies (petit mal absences, various forms of myoclonic epilepsies and tonic-clonic grand mal seizures). partial (focal) epilepsies either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Singapore - English - HSA (Health Sciences Authority)

aguettant asia pacific pte. ltd. - sodium valproate - injection, solution - sodium valproate 400mg/4ml

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); sodium methyl hydroxybenzoate; citric acid; brilliant scarlet 4r; hyetellose; sodium propyl hydroxybenzoate; saccharin sodium; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; kaolin; maize starch - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: hypromellose; stearic acid; indigo carmine aluminium lake; purified talc; calcium silicate; citric acid monohydrate; amaranth aluminium lake; macrogol 6000; povidone; hyprolose; titanium dioxide; diethyl phthalate; polyvinyl acetate phthalate; magnesium stearate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - metamizole sodium (unii: vsu62z74on) (metamizole - unii:934t64rmnj) -

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - metamizole sodium (unii: vsu62z74on) (metamizole sodium - unii:vsu62z74on) -